MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
133
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. MapLight Therapeutics Inc. market cap is $356.8M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. MapLight Therapeutics Inc. 52 week high is $40.43 as of November 21, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. MapLight Therapeutics Inc. 52 week low is $6.06 as of November 21, 2026.
MapLight Therapeutics Inc. stock price today is $5.94.
MapLight Therapeutics Inc. stock price yesterday was $6.42.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. MapLight Therapeutics Inc.'s P/E ratio is -1.18.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. MapLight Therapeutics Inc. P/B ratio is 0.8018.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. MapLight Therapeutics Inc. 50-day moving average is $8.77.